Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model by 源��듅�뾽 et al.
© 2013 Kim et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
OncoTargets and Therapy 2013:6 1463–1469
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1463
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S51986
Transient elastography-based risk estimation  
of hepatitis B virus-related occurrence of 
hepatocellular carcinoma: development and 
validation of a predictive model
Do Young Kim1,2,4,*
Ki Jun song3,4,*
seung Up Kim1,2,4
eun Jin Yoo1
Jun Yong Park1,2,4
sang hoon ahn1,2,4
Kwang-hyub han1,2,4
1Department of internal Medicine,  
2institute of gastroenterology, 
3Department of Biostatistics, Yonsei  
University college of Medicine,  
4liver cirrhosis clinical research  
center, seoul, Korea
*These authors contributed equally  
to this work
correspondence: seung Up Kim 
Department of internal Medicine,  
Yonsei University college of Medicine,  
50 Yonsei-ro, seodaemun–gu,  
seoul 120-752, south Korea 
Tel +82 2 2228 1982 
Fax +82 2 393 6884 
email ksukorea@yuhs.ac
Background: The purpose of this study was to develop and validate a novel transient elastog-
raphy-based predictive model for occurrence of hepatocellular carcinoma (HCC).
Methods: A total of 1,250 patients with chronic hepatitis B and baseline liver stiffness values 
were recruited between May 2005 and December 2007. The predictive model for HCC occurrence 
was constructed based on a Cox proportional hazards model. We estimated baseline disease-free 
probabilities at 3 years. Discrimination and calibration were used to validate the model.
Results: HCC occurred in 56 patients during a median follow-up of 30.7 months. Multivariate 
analysis revealed that age, male gender, and liver stiffness values were independent predic-
tors of HCC (all P,0.05), whereas hepatitis B virus DNA $20,000 IU/L showed borderline 
statistical significance (P=0.0659). We developed a predictive model for HCC using these 
four variables, which showed good discrimination capability, with an area under the receiver 
operating characteristic curve (AUROC) of 0.806 (95% confidence interval 0.738–0.874). We 
used the bootstrap method to assess discrimination. The AUROC remained largely unchanged 
between iterations, with an average value of 0.802 (95% confidence interval 0.791–0.812). The 
predicted risk of occurrence of HCC calibrated well with the observed risk, with a correlation 
coefficient of 0.905 (P,0.001).
Conclusion: This novel model accurately estimated the risk of HCC occurrence in patients 
with chronic hepatitis B.
Keywords: hepatocellular carcinoma, transient elastography, prediction, hepatitis B
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and is a 
serious public health problem, particularly in association with chronic viral hepatitis. 
Several factors, such as chronic hepatitis B virus (HBV) or hepatitis C virus infection, 
cirrhosis, alcohol consumption, and obesity have been identified as risk factors for 
development of HCC.1–5 Moreover, the observation that over half of HCC cases and 
deaths are estimated to occur in far Eastern countries, including Korea, Taiwan, 
and China, indicates that HBV infection has a major influence on worldwide HCC 
epidemiology.6
Because timely and appropriate treatment and monitoring could reduce the inci-
dence of HCC or detect early cancers in those with a high probability of progressing 
to HCC, it is important to be able to predict HCC occurrence in patients with chronic 
hepatitis B (CHB). Both host and viral factors can affect progression of CHB to cirrhosis 
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or HCC in HBV-infected patients. Age, male gender, and 
elevated alanine aminotransferase (ALT) levels are host-
related factors that predict occurrence of HCC.7 Virologic 
factors associated with the risk of HCC in patients with 
CHB include hepatitis B e-antigen (HBeAg) positivity, high 
serum HBV DNA levels, genotype C, and precore or core 
promoter mutations.8–12 However, few risk estimation and 
predictive models for HCC occurrence have been developed 
and validated in patients with CHB based on these host and 
virologic factors.10,13,14
The degree of liver fibrosis is also significantly related to 
the risk of HCC occurrence.15,16 However, to date, the severity 
of liver fibrosis has not been incorporated in models, because 
histologic assessment of liver fibrosis by liver biopsy is not 
always feasible in clinical practice and may cause patient 
discomfort and pain, and even serious complications such 
as bleeding or biopsy-related mortality.17 Further, sampling 
error and interobserver and intraobserver variability of the 
liver biopsy can impede its diagnostic accuracy.18 Recently, 
liver stiffness measurement using transient elastography 
(FibroScan®, Echosens, Paris, France) has been introduced as 
a promising noninvasive method for assessing the degree of 
liver fibrosis, with considerable accuracy and high reproduc-
ibility in HBV-infected patients.19,20 Stratified baseline liver 
stiffness values in patients with CHB have been demonstrated 
as an independent predictor of HCC occurrence in a recent 
study, where the 3-year cumulative incidence of HCC was 
significantly higher in patients with a higher liver stiffness 
value (.8 kPa).16
Thus, the aim of this study was to investigate whether 
the degree of liver fibrosis assessed by transient elastography 
shows a significant correlation with the risk of HCC, and if 
so, to construct and validate a transient elastography-based 
predictive model for HCC occurrence in a cohort of patients 
with CHB.
Patients and methods
Predictive model derivation
We prospectively identified 1,250 patients with CHB who 
visited the outpatient clinic and received a transient elas-
tography examination at our institution between May 2005 
and December 2007. We then excluded 140 patients who 
did not provide written informed consent, had unreliable 
transient elastography data, or had insufficient clinical data 
for statistical analysis. Finally, the study cohort consisted of 
1,110 patients, and this was used to develop the predictive 
model for HCC occurrence. The database for our cohort 
included information on patient demographics, laboratory 
results, and liver stiffness values at the time of enrollment. 
A trained medical reviewer collected patient data from 
medical charts. The study was approved by the independent 
institutional review board of Severance Hospital, Yonsei 
University College of Medicine, Seoul, Korea.
liver stiffness measurement
Liver stiffness measurement was performed according to 
previously reported methods.21,22 Briefly, liver stiffness was 
measured on the right lobe of the liver through the intercostal 
space, with the patient lying in the dorsal decubitus position 
with the right arm in maximal abduction. The operator located 
a liver portion that was at least 6 cm thick and free of large 
vascular structures, and pressed the probe button to com-
mence the measurement. Only one experienced technician, 
blind to the patient clinical data, performed the transient 
elastography, with results expressed in kilopascals. Only 
transient elastography examinations with at least 10 validated 
liver stiffness measurements, a success rate of at least 60%, 
and an interquartile range to median value ratio #0.3 were 
considered reliable. Any liver stiffness value that did not 
satisfy these conditions was considered unreliable and was 
excluded from further analysis. When a reliable examination 
was conducted, the median value of the successful measure-
ments was selected as a representative liver stiffness value 
in a given patient.
Diagnosis of cirrhosis and hcc
Liver cirrhosis was clinically diagnosed as follows: platelet 
count ,100,000/µL and ultrasonographic findings sugges-
tive of cirrhosis, including a blunted, nodular liver edge 
accompanied by splenomegaly (.12 cm); esophageal or 
gastric varices; or overt complications of liver cirrhosis.23,24 
HCC was diagnosed histologically or clinically based on 
the guidelines of the American Association for the Study 
of Liver Diseases.25 Briefly, HCC was diagnosed for 
tumors .2 cm when typical features of HCC were detected 
(hypervascularity and washout in the portal/venous phase) by 
one dynamic imaging technique and when the alfa fetoprotein 
level was .200 ng/mL. For nodules measuring 1–2 cm, it 
was necessary to detect typical features of HCC using two 
dynamic imaging techniques. Ultrasonography was repeated 
after 3 months for tumors ,1 cm.
statistical analyses
All statistical analyses were conducted using SAS  version 
9.2 software (SAS Institute, Cary, NC, USA). The predictive 
model of HCC occurrence was constructed based on 
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a Cox proportional hazards model, which was used to iden-
tify independent predictors of HCC occurrence with their 
respective β-regression coefficient, P-value, hazard ratio, 
and 95% confidence interval (CI). The median follow-up 
period was 30.7 (range 24.0–50.9) years, and we estimated 
baseline disease-free probabilities at 3 years.
 1 – P
0
expΣβiXi 
where P
0
 is the baseline disease-free probability and βi is the 
β-regression coefficient for the ith independent covariate. 
The model was validated by discrimination and calibration. 
Discrimination was assessed using the receiver operat-
ing characteristic curve, area under the receiver operating 
characteristic curve (AUROC), sensitivity, and specificity. 
We calculated the predicted risk of HCC occurrence at 
3 years based on our predictive model and then estimated the 
observed Kaplan–Meier risk of HCC to assess calibration. 
Kaplan–Meier estimates were plotted against the predicted 
risk in the group to create a calibration chart.
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the cohort 
(n=1,110). The mean age was 50 years, and there were 
760 males and 350 females. Cirrhosis was clinically diag-
nosed in 182 (16.3%) patients. The median ALT level and 
liver stiffness value was 40 IU/L and 7.7 kPa, respectively. 
HBeAg positivity was observed in 400 (36.0%) patients, 
and HBV DNA $20,000 IU/L was observed in 349 (31.4%) 
patients. Fifty-six patients developed HCC during the study 
period. The one-year, 2-year, and 3-year cumulative HCC 
incidence was 0.90%, 1.45%, and 6.05%, respectively.
Multivariate Cox proportional  
hazards model
First, the influence of each variable (age, gender, clinically 
diagnosed cirrhosis, diabetes mellitus, previous or ongoing 
antiviral treatment, body mass index, alpha fetoprotein, 
serum albumin, total bilirubin, aspartate aminotransferase, 
ALT, prothrombin time, platelet count, HBeAg positivity, 
HBV DNA, and liver stiffness value) was tested in a univari-
ate analysis. Only age, male gender, liver stiffness value, 
and HBV DNA were statistically significant in univariate 
analysis (Table 2). A subsequent multivariate analysis was 
then performed using these four variables. Table 2 shows 
the β-regression coefficient estimates with the multivariate 
Cox proportional hazards model. In our cohort, age, male 
gender, and liver stiffness values were selected as indepen-
dent predictors of HCC occurrence (all P,0.05), and HBV 
DNA $20,000 IU/L showed borderline statistical signifi-
cance (P=0.0659). The other variables was not statistically 
significant (P.0.1).
Development of a predictive  
model of HCC occurrence
In addition to the three independent variables (age, male 
gender, and liver stiffness value), HBV DNA $20,000 IU/L 
was also incorporated as a constituent variable to develop 
the predictive model for HCC occurrence, which has been 
a generally accepted significant risk factor for HCC.9 
Table 2 Univariate and multivariate analysis to identify 
independent predictors of hcc occurrence
Factor Univariate Multivariate
P-value Beta P-value Hazard ratio 
(95% CI)
age ,0.0001 0.0531 0.0003 1.054  
(1.025–1.085)
Male gender 0.0140 1.106 0.0044 3.022  
(1.411–6.473)
lsM value ,0.0001 0.0486 ,0.0001 1.050  
(1.034–1.065)
hBV Dna  
$20,000 iU/l
0.0465 0.5097 0.0659 1.665  
(0.967–2.866)
Abbreviations: HCC, hepatocellular carcinoma; CI, confidence interval; LSM, liver 
stiffness measurement; hBV, hepatitis B virus.
Table 1 Baseline characteristics of the cohort (n=1,110)
Characteristics Values
Demographic data
 age, years 50 (21–81)
 Male gender 760 (68.5)
 clinically diagnosed cirrhosis 182 (16.3)
 Diabetes mellitus 31 (2.8)
 Previous or ongoing antiviral treatment 420 (37.8)
 Body mass index, kg/m2 27 (22–35)
laboratory data
 serum albumin, g/dl 4.5 (2.8–6.3)
 Total bilirubin, mg/dl 0.9 (0.2–3.8)
 aspartate aminotransferase, iU/l 38 (12–167)
 alanine aminotransferase, iU/l 40 (8–172)
 Prothrombin time, % 92 (45–100)
 Platelet count, ×109/l 160 (45–520)
 hBeag positivity 400 (36.0)
 high hBV Dna $20,000 iU/l 349 (31.4)
liver stiffness measurement
 liver stiffness, kPa 7.7 (2.9–70)
 interquartile range, kPa 1.7 (0.1–9.8)
 success rate, % 95 (64–100)
Note: Variables are expressed as median (range) or n (%).
Abbreviations: hBeag, hepatitis B e-antigen; hBV, hepatitis B virus.
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This newly developed predictive model showed fairly good 
discrimination capability, with an AUROC of 0.806 (95% 
CI 0.738–0.874, Figure 1).
 Probability =1 − PA 
 A = exp (0.05306 × age + 1.106 × male gender 
+ 0.04858 × liver stiffness values + 0.50969 
× HBV DNA $20,000 IU/L)
Discrimination and calibration
We used the bootstrap method, in which 1,000 random sam-
ples drawn with replacement from the original data set and the 
coefficients were recalculated in each bootstrap sample. The 
AUROCs remained largely unchanged between iterations, 
with an average AUROC of 0.802 (95% CI 0.791–0.812). 
We plotted a calibration chart for predicted and observed risk 
of HCC occurrence (Figure 2). The predicted risk of HCC 
occurrence calibrated well with the observed risk, with a 
correlation coefficient of 0.905 (P,0.001).
Discussion
This prospective cohort study was undertaken to develop 
a clinically useful predictive model for HCC occurrence 
in patients with CHB using a single tertiary hospital-based 
cohort from South Korea, and the resulting predictive model 
was validated internally.
Although extensive studies have identified risk factors 
associated with HCC occurrence in patients with CHB, 
few mathematically modeled risk estimations have been 
proposed.8,10,14,26,27 The use of hard-to-obtain variables, such 
as HBeAg and specific HBV mutations (precore or core 
promoter), as constituent variables or selecting naïve patients 
for antiviral treatment to develop a predictive model for 
HCC occurrence had made it difficult to apply universally 
to all patients infected with HBV.14 In this regard, our new 
model has the advantage that four simple, not exhaustive, 
noninvasively obtainable, and objective variables of age, male 
gender, HBV DNA, and liver stiffness values were included. 
Although statistical significance was not identified, even in 
the univariate analysis, we tried to adjust the influence of 
antiviral treatment. Finally, our new predictive model for 
HCC occurrence was accurate and reliable, with an AUROC 
of 0.806, similar to that of a study by Yang et al in which the 
AUROC of the risk scores was 0.811,10 and with a predicted 
risk correlating well with observed risk (correlation coef-
ficient of 0.905).
The suggested formula for 3-year probability of HCC 
occurrence, ie, 1 − PA (A = exp [0.05306 × age + 1.106 × male 
gender + 0.04858 × liver stiffness value + 0.50969 × HBV 
DNA $20,000 IU/L]), is a revision of what we have 
previously reported, in which age, gender, cirrhosis, HBV/
hepatitis C virus infection, ALT, alfa fetoprotein, and alcohol 
consumption were included as variables.27 It may be argued 
that cirrhosis, which has been the single most important risk 
factor for initiating a surveillance program to detect HCC 
occurrence early and was selected as a significant predictor 
of HCC occurrence in univariate analysis of our study, should 
be included in this model. However, a histologic diagnosis of 
cirrhosis is not feasible in clinical practice, and no established 
and sufficiently validated clinical diagnostic criteria for cir-
rhosis are available, which is the reason why cirrhosis has 
not been incorporated into several previous risk prediction 
models for HCC occurrence. Further, increasing evidence has 
indicated that liver stiffness values, measured objectively by 
transient elastography, correspond accurately to the severity 
of liver fibrosis in both HBV and hepatitis C virus-related 
chronic liver diseases and that baseline liver stiffness values 
in patients with CHB predict HCC occurrence better than 
clinical diagnostic criteria of cirrhosis.23,24 All these results 
help to explain the superiority of liver stiffness values for 
diagnosing compensated cirrhosis. Thus, apart from the 
finding that liver stiffness value, not clinically diagnosed 
cirrhosis, was selected as one of the independent predictors 
of HCC occurrence in the multivariate analysis, our model 
might have been powered by liver stiffness values which are 
noninvasive and more reproducible than liver biopsy with a 
potential sampling error and interpretational variability, and 
more reliable and accurate than clinical diagnostic criteria 
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Figure 1 receiver operating characteristics curve of the model. When we used the 
bootstrap method to assess discrimination, aUrOcs remained largely unchanged 
between iterations, with an average AUROC of 0.802 (95% confidence interval 
0.791–0.812).
Abbreviation: aUrOc, area under the receiver operating characteristic curve.
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for cirrhosis without sufficient validations. In addition, 
when the liver stiffness value was removed from our model, 
AUROC declined significantly from 0.806 to 0.713 (95% CI 
0.689–787; P=0.0296), which clearly indicates that the liver 
stiffness value can enhance the performance of our prediction 
model for HCC occurrence.
In addition to cirrhosis, ambiguous variables such as ALT, 
alfa fetoprotein, and alcohol, were removed in our revised 
model. Although several studies have shown that these fac-
tors might be closely associated with HCC occurrence,2,28,29 
fluctuations in serum ALT levels and the influence of other 
conditions on alfa fetoprotein levels have made these markers 
unreliable for predicting HCC occurrence. Further, informa-
tion on the amount of alcohol consumed by each patient is still 
dependent solely on patient interview, without any objective 
measure of alcohol consumption, and no definition of heavy 
alcohol consumption exists.
The finding that HBeAg status was not a risk factor 
for HCC occurrence in our study is in line with previous 
studies from Hong Kong and Taiwan,9 but disagrees with 
another report from Taiwan where a risk score incorporating 
gender, age, ALT level, HBeAg, and HBV DNA level was 
developed from a community-based untreated patient cohort 
with CHB.10 Therefore, it would be ideal to derive a model 
for predicting HCC occurrence in patients with CHB using 
multinational data with a large sample size, considering that 
a heterogeneous study population even in the same country 
could generate different risk factors associated with HCC 
occurrence. Unfortunately, because we used a less sensitive 
hybridization capture assay for measuring HBV DNA levels, 
we were not able to lower the cutoff of HBV DNA levels 
below 20,000 IU/mL during the study period.
Finally, antiviral treatment was not selected as an inde-
pendent predictor of HCC occurrence. This result can be 
explained by the current antiviral treatment protocol for 
patients with active hepatitis to suppress viral replication 
and HCC occurrence according to most guidelines of the 
American Association for the Study of Liver Diseases, 
European Association for the Study of the Liver, and Asia 
Pacific Association for the Study of the Liver.30–32
Our predictive model for HCC occurrence will be useful 
for several purposes in clinical practice. First, it will provide 
an optimal surveillance strategy for patients with CHB, which 
are not covered by current management recommendations. 
More intensive follow-up for HCC surveillance will be 
needed for patients assessed as having a high probability 
of HCC occurrence, whereas those with a low risk could 
be monitored with a less vigorous surveillance protocol. 
Second, because HBV DNA and liver stiffness values can 
change during the natural course of the disease, or by antiviral 
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Figure 2 calibration chart for predicted versus observed risk of occurrence of hcc. The predicted risk of occurrence of hcc calibrated well with the observed risk, with 
a correlation coefficient of 0.905 (P,0.001).
Abbreviation: hcc, hepatocellular carcinoma.
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treatment, and changes in these values also have a significant 
influence on HCC occurrence,16 dynamic changes in the risk 
of HCC occurrence could be theoretically monitored by our 
new predictive model. If this hypothesis can be validated in 
future studies, patient compliance in a follow-up protocol 
and initiation of treatment could be enhanced by showing 
them the changing risk probability.
Several issues remain unresolved in our study. First, 
although use of transient elastography as a tool for estima-
tion of liver fibrosis in predicting HCC occurrence is a novel 
approach, the use of transient elastography is still confined to 
referral hospitals. Thus, a limitation on the widespread use of 
our new model is anticipated. However, because use of tran-
sient elastography in clinical practice is currently increasing, 
this new predictive model in our pilot trial could be a corner-
stone for future studies. Second, the risk calculation for HCC 
occurrence in our study was based on the probability of HCC 
occurrence at 3 years, considering the median follow-up period 
of our study cohort (30.7 months). Thus, more long-term 
follow-up seems needed to assess accurately the risk of HCC 
occurrence. Third, a potentially overestimated HCC incidence 
rate could be another issue, because our study subjects were 
recruited from a tertiary hospital. Last, external validation 
of our model in different countries with different ethnicities 
should be conducted for widespread practical use.
In conclusion, we have developed a simple transient 
elastography-based predictive model for HCC occurrence in 
patients with CHB. Although the performance of this new 
model was reasonable, based on an internal validation, the 
implementation of transient elastography in private clinics 
and external validation of our model are necessary before 
this new model can be used in the clinic.
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